Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Clinical trial NCT03964090 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03964090
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-27
- Primary completion
- 2027-07-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.